Kombiglyze XR gets green light from KFDA

Published: 2012-04-16 06:58:00

Updated: 2012-04-16 06:58:00

The Korea Food and Drug Administration said Thursday it approved AstraZeneca and Bristol-Myers Squibb’s combo drug Kombiglyze XR (saxagliptin and metformin HCl extended-release), five months after initial approval of Onglyza.

The once-daily Kombiglyze is a dipeptidyl peptidase-4 (DPP4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.